Skip to main content

Day: January 23, 2024

Gildan Provides Timeline of Events Leading Up to CEO’s Removal

MONTREAL, Jan. 23, 2024 (GLOBE NEWSWIRE) — Gildan Activewear Inc. (GIL: TSX and NYSE) (“Gildan” or “the Company”) today provides details on the timeline of events leading up to Glenn Chamandy’s removal as CEO. For more than a month, Browning West and Glenn Chamandy have claimed that the Board of Directors carried out a flawed CEO succession process. The facts, backed by years of documentation and Mr. Chamandy’s own words, tell a much different story. In December 2021, the Board and Mr. Chamandy agreed to an orderly three-year succession plan. Had Mr. Chamandy abided by his agreement, rather than attempting to entrench himself as CEO, the recent turmoil at Gildan would have been avoided. We now know that Mr. Chamandy never intended to abide by the agreed succession plan. He made that clear when he told the Globe and Mail on December...

Continue reading

Celestica Recognized as one of Canada’s Top 100 Employers for Young People for 2024

TORONTO, Jan. 23, 2024 (GLOBE NEWSWIRE) — Celestica Inc. (NYSE, TSX: CLS), a leader in design, manufacturing, hardware platform and supply chain solutions for the world’s most innovative companies, has been named one of Canada’s Top 100 Employers for Young People for 2024 by Mediacorp Canada Inc., organizers of the annual Canada’s Top 100 Employers project. “We are honoured to be named among Canada’s Top 100 Employers for Young People in 2024,” said Rob Mionis, President and Chief Executive Officer, Celestica. “At Celestica, we recognize that our employees play an important role in our company’s success and we strive to create a collaborative environment that fosters innovation, empowers people and leverages individual expertise.” Leila Wong, Chief Human Resources Officer, Celestica added, “Our young people play a vital role...

Continue reading

SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

SIOUX FALLS, S.D., Jan. 23, 2024 (GLOBE NEWSWIRE) — SAB Biotherapeutics, Inc. (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing fully-human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced that it received notice from The Nasdaq Stock Market LLC (“Nasdaq”) on January 23, 2024 informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the “Rule”) for continued listing on the Nasdaq Capital Market. On January 23, 2023, SAB received notice from Nasdaq that the Company was not in compliance with the Rule, as its common shares failed to meet a closing bid price of $1.00 or more for 30 consecutive business...

Continue reading

Shapeways Announces 100% YOY Growth in its Multi-Million-Dollar Automotive Vertical

Expanded Tier 1 Supplier & OEM Awards Accelerate Growth NEW YORK, Jan. 23, 2024 (GLOBE NEWSWIRE) — Shapeways Holdings, Inc. (NASDAQ: SHPW), a global leader in the large and fast-growing digital manufacturing industry, announced today a landmark 100% year-over-year growth within its multi-million-dollar automotive business. Shapeways Enterprise Manufacturing Solutions continues to secure Tier 1 supplier and OEM direct multi-year production volume, including a recently expanded $1.5M contract with an industry-leading American automotive manufacturer. Aidan O’Sullivan, General Manager of Enterprise Manufacturing Solutions at Shapeways, noted, “Flexibility and adaptability are key in meeting our customers’ dynamic production demands. Whether it’s rapid, iterative prototyping or market shifts between electric and conventional...

Continue reading

Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock

SAN MATEO, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) — Sagimet Biosciences Inc. (“Sagimet”) (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the commencement of an underwritten public offering of 9,000,000 shares of its Series A common stock. All of the shares in the proposed offering are to be sold by Sagimet. In addition, Sagimet expects to grant the underwriters a 30-day option to purchase up to an additional 1,350,000 shares of its Series A common stock in the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Goldman Sachs & Co. LLC,...

Continue reading

Vision Sensing Acquisition Corp. Received Nasdaq Delisting Determination Letter and Intends to Appeal the Determination and Request a Stay Pending the Appeal Hearing

NEW YORK, Jan. 23, 2024 (GLOBE NEWSWIRE) — Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) (the “Company” or “VSAC”), a special purpose acquisition company, announced today that it received a staff determination letter (the “Letter”), on January 17, 2024, from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company of the determination from the Nasdaq Staff (the “Staff”) to delist the Company’s securities from The Nasdaq Stock Market, because, as of December 26, 2023, the Company had not regained compliance with the requirement set forth Listing Rule 5450(b)(2)(A) that requires the market value of the Company’s listed securities to be $50,000,000 or more. The Letter also states that since the Company has not yet filed its Form...

Continue reading

Baker Hughes Announces Fourth-Quarter and Full-Year 2023 Results

Fourth-quarter highlightsIET orders of $3,030 million, the fifth consecutive quarter above $3 billion. Net income attributable to the Company of $439 million, up $257 million year-over-year. GAAP diluted EPS of $0.43 and adjusted diluted EPS* of $0.51. Adjusted EBITDA* of $1,091 million, above $1 billion for the first time in company history. Cash flows from operating activities were $932 million and free cash flow* was $633 million. Shareholder distributions of $521 million, including $320 million of share repurchases.Full-year highlightsIET orders of $14.18 billion, 12% higher than last year’s prior record level. Net income attributable to the Company of $1,943 million, up $2,544 million year-over-year. Adjusted EBITDA* of $3.76 billion, increasing 26% year-over-year. GAAP diluted EPS of $1.91 and adjusted diluted EPS* of...

Continue reading

First Busey Corporation Announces 2023 Fourth Quarter Earnings

CHAMPAIGN, Ill., Jan. 23, 2024 (GLOBE NEWSWIRE) — First Busey Corporation (Nasdaq: BUSE)Net Income of $25.7 millionDiluted EPS of $0.46Fourth Quarter 2023 HighlightsAdjusted net income1 at $29.1 million, or $0.52 per diluted common share Entered into a definitive agreement to acquire Merchants & Manufacturers Bank Corporation (“M&M”), the holding company for Merchants & Manufacturers Bank (“M&M Bank”) Executed a two-part balance sheet repositioning related to the securities portfolio, expected to be both capital and earnings accretive Non-performing assets declined 34.4% during the fourth quarter of 2023, to $7.9 million, now representing 0.06% of total assets Annualized quarterly net charge-off ratio of 0.02% and full year net charge-off ratio of 0.03% Tangible book value per common share1 of $16.62...

Continue reading

Timbercreek Financial Declares January 2024 Dividend

TORONTO, Jan. 23, 2024 (GLOBE NEWSWIRE) — Timbercreek Financial (TSX: TF) (the “Company”) is pleased to announce that it has declared a monthly cash dividend of $0.0575 per common share (“Common Share”) of the Company to be paid on February 15, 2024 to holders of Common Shares of record on January 31, 2024. The Company also offers a Dividend Reinvestment Plan (the “Plan”), which is eligible to holders of Common Shares and provides a convenient means to purchase additional Common Shares by reinvesting cash dividends at a potential discount and without having to pay commissions, service charges or brokerage fees. Pursuant to the Plan and at the discretion of Timbercreek Capital Inc., the Manager, Common Shares will be acquired in the open market at prevailing prices or issued from treasury at 98 percent of the average market price...

Continue reading

Stallion Uranium Announces Listed Issuer Financing Exemption (LIFE) Non-Brokered Private Placement of Units

Not for distribution to United States Newswire Services or for dissemination in the United States VANCOUVER, British Columbia, Jan. 23, 2024 (GLOBE NEWSWIRE) — Stallion Uranium Corp. (the “Company” or “Stallion”) (TSX-V: STUD; OTCQB: STLNF; FSE: HM40) is pleased to announce that it is undertaking a non-brokered private placement (the “Offering“) for aggregate gross proceeds of up to C$4,000,000, with an over-allotment option to raise up to an additional C$1,000,000 of Units (as defined below), from the sale of the following:up to 4,687,500 Federal flow-through units of the Company (each, an “FFT Unit”) at a price of C$0.32 per FFT Unit; up to 4,166,667 Saskatchewan flow-through units of the Company (each, a “SFT Unit”) at the price of C$0.36 per SFT Unit; and up to 4,545,454 units of the Company...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.